1	HIV-1 evolutionary dynamics under non-suppressive antiretroviral therapy
2	
3	Steven A. Kemp ^{1*+} , Oscar J. Charles ²⁺ , Anne Derache ³ , Werner Smidt ³ , Darren P. Martin ⁴ , on behalf of
4	the ANRS 12249 TasP Study Group, Deenan Pillay ² , Richard A. Goldstein ² & Ravindra K. Gupta ^{2,3}
5	
6	^{1.} Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
7	^{2.} Division of Infection & Immunity, University College London, London, UK
8	^{3.} Africa Health Research Institute, Durban, South Africa
9 10	^{4.} Department of Integrative Biomedical Sciences, University of Cape Town, South Africa
11	[†] Authors contributed equally
12	
13	Address for correspondence:
14	Steven A Kemp
15	Cambridge Institute for Therapeutic Immunology and Infectious Diseases
16	Jeffrey Cheah Biomedical Centre
17	Cambridge CB2 0AW, UK
18	<u>sk2137@cam.ac.uk</u>
19	
20	or
21	
22	Ravindra K Gupta
23	Cambridge Institute for Therapeutic Immunology and Infectious Diseases
24	Jeffrey Cheah Biomedical Centre
25	Cambridge CB2 0AW, UK
26	<u>Rkg20@cam.ac.uk</u>
27	
28	
29	
30	
31	
32	
33	
34	

35 Abstract

Prolonged virologic failure on 2nd-line protease inhibitor (PI) based ART without emergence of major 36 37 protease mutations is well recognised and provides an opportunity to study within-host evolution in 38 long-term viraemic individuals. Using next-generation sequencing and in silico haplotype 39 reconstruction we analysed whole genome sequences from longitudinal plasma samples of eight chronically infected HIV-1 individuals failing 2nd-line regimens from the ANRS 12249 TasP trial. On 40 non-suppressive ART, there were large fluctuations in synonymous and non-synonymous variant 41 42 frequencies despite stable viraemia. Reconstructed haplotypes provided evidence for selective 43 sweeps during periods of partial adherence, and viral haplotype competition during periods of low 44 drug exposure. Drug resistance mutations in reverse transcriptase (RT) were used as markers of viral 45 haplotypes in the reservoir and their distribution over time indicated recombination. We independently observed linkage disequilibrium decay, indicative of recombination. These data 46 highlight dramatic changes in virus population structure that occur during stable viremia under non 47 48 suppressive ART. 49

...

50

51

52 Introduction

Even though HIV-1 infections are most commonly initiated with a single founder virus¹, acute and 53 54 chronic disease are characterised by extensive inter- and intra-patient genetic diversity^{2,3}. The rate 55 and degree of diversification is influenced by multiple factors, including selection pressures imposed by the adaptive immune system, exposure of the virus to drugs, and tropism/fitness constraints 56 relating to replication and cell-to-cell transmission in different tissue compartments^{4,5}. During HIV-1 57 infection, high rates of reverse transcriptase- (RT) related mutation and high viral turnover during 58 replication result in swarms of genetically diverse variants⁶ which co-exist as quasispecies^{7,8}. The 59 existing literature on HIV-1 intrahost population dynamics is largely limited to untreated infections, 60 in subtype B infected individuals⁹⁻¹². These works have shown non-linear diversification of virus both 61 62 towards and away from the founder strain during chronic untreated infection.

63

64 Viral population dynamics in long-term viraemic antiretroviral therapy (ART) treated individuals have 65 not been characterised. HIV-1 rapidly accumulates drug-resistance associated mutations (DRMs), particularly during non-suppressive 1st-line ART^{5,13}. As a result, ART-experienced patients failing 1st-66 line regimens for prolonged periods of time are characterised by high frequencies of common 67 nucleoside reverse transcriptase (NRTI) and non-nucleoside reverse transcriptase (NNRTI) DRMs 68 such as M184V, K65R and K103N¹⁴. Routinely, 2nd-line ART regimens consist of two NRTIs in 69 conjunction with a boosted protease inhibitor (PI). Although PI DRMs are uncommonly reported¹⁵, a 70 situation that differs for less potent drugs used in the early PI era⁵, multiple studies have indicated 71 that diverse mutations accumulating in the *qaq* gene during PI failure might impact PI 72 susceptibility¹⁶⁻²². Common pathways for these diverse mutations have, however, been difficult to 73 74 discern, likely reflecting multiple routes to drug escape.

75

Prolonged virological failure on PI-based regimens without the emergence of PI DRMs provides an opportunity to study evolution under partially suppressive ART. The process of selective sweeps in the context of HIV-1 infection has previously been described^{23,24}. Although major PI DRMs and other non-synonymous mutations in regulatory regions such as *pol*, can significantly lower fitness^{2,25,26}, these studies typically are oblivious to temporal sequencing.

81

We have deployed next-generation sequencing of stored blood plasma specimens from patients in the Treatment as Prevention (TasP) ANRS 12249 study²⁷, conducted in Kwazulu-Natal, South Africa. All patients were infected with HIV-1 subtype C and characterised as failing 2nd-line regimens containing Lopinavir and Ritonavir (LPV/r), with prolonged virological failure in the absence of major

known PI mutations²⁸. In this manuscript, we report details of evolutionary dynamics during nonsuppressive 2nd-line ART. By sampling patients consistently over two or more years, we propose that
ongoing evolution is driven by the dynamic flux between genetic drift, fitness driven selection and
recombination, exemplified by resistance mutations that have undergone reassortment across
haplotypes through recombination.

91

92 Results

93 **Patient Characteristics**

Eight south African patients with virological failure of 2nd-line PI-based ART, with between three and 94 95 eight timepoints and viraemia >1000 copies/ml were selected from the French ANRS TasP trial for 96 viral dynamic analysis. Collected patient metadata included viral loads, regimens and time since ART 97 initiation (Table 1). HIV RNA was isolated from venous blood samples and subject to whole-genome 98 sequencing (WGS) using Illumina technology; from this whole-genome haplotypes were 99 reconstructed using sites with a depth of \geq 100 reads (**Supplementary Figure 1**). Prior to 100 participation in the TasP trial, patients accessed 1st-line regimens for an average of 5.6yrs (±2.7yrs). At baseline enrolment into TasP (whilst failing 1^{st} -line regimens), the median patient viral load was 101 4.96×10^{10} copies/ml (IQR: $4.17 \times 10^{10} - 5.15 \times 10^{10}$); twelve DRMs were found at a threshold of >2%; 102 103 the most common of which were the RT mutations. K103N, M184V and P225H, which are consistent 104 with previous use of d4T, NVP, EFV and FTC/3TC. Six of the eight patients had minority frequency 105 DRMs associated with PI failure (average 6.4%) which were usually seen only in one sample per 106 patient throughout the longitudinal sampling. Observed mutations included L231, I47V, M46I/L, 107 G73S, V82A, N83D and I85V (Supplementary Tables 1a-3c). Viral populations of four of the eight 108 patients also carried major integrase strand inhibitor (INSTI) mutations, also at minority frequencies 109 (average 5.0%) and also usually at single timepoints (T97A, E138K, Y143H, Q148K). Of note, patients 110 were maintained on protease inhibitors during viremia as poor adherence was suspected as the 111 reason for ongoing failure. Sanger sequencing of all subtype C viruses was undertaken during routine 112 clinical monitoring and was consistent with NGS data (Supplementary Tables 1a-3c) regarding the 113 absence of PI DRMS.

114

115 SNP frequencies and measures of diversity/divergence over time

WGS data was used to measure the changing frequencies of viral single nucleotide polymorphisms (SNPs) relative to a dual-tropic subtype C reference sequence (AF411967) within individuals over time (Figure 1a-b). The number of longitudinal synonymous SNPs mirrored the number of nonsynonymous SNPs, but the former were two-to-three-fold more common. Diversification was

considered by counting the number of SNPs relative to the reference sequence. There were dynamic changes in the numbers of SNPs over time, with both increases and decreases in numbers of SNPs, suggesting population competition, and/or the occurrence of selective sweeps. From timepoint two onwards (all patients now on 2^{nd} -line, PI-containing regimens for >6 months), all patients (except 28545) had increases in both synonymous and non-synonymous SNPs.

125

In previous literature, viral populations within untreated, chronically infected HIV-1 patients have been shown to revert towards the founder or infecting virus states⁹. We repeated this analysis with our chronically infected, but treated, HIV-1 population, considering separately the earliest consensus sequence, HIV-1 subtype C consensus and M group consensus sequences as founder strains. Divergence from the founder strain per patient timepoint was measured by calculating the genetic distance between patient and founder for each longitudinal sample.

132

To assess if 1) there was a general trend of reversion to founder and 2) time was an explanatory variable to that trend, we utilised a Linear Mixed Effects Model (LMEM). Divergence from the founder was modelled as the response, each patient was treated as a random effect, and time from first patient sample treated as a fixed effect "time". Modelling the whole genome sequences indicated that there was no significant effect of time (in months) on viral diversification or reversion to the infecting/baseline strain, or ancestral C state (**Figures 1C-D, Supplementary table 4**).

139

140 When assessing the constituent 1000 bp genomic regions of each alignment, four genomic regions 141 were significant for divergence from the ancestral C state, indicating time in months impacted viral 142 divergence. This revealed that in portions of the genome (pol, vpu and env) there was sufficient 143 statistical support to confirm that there was ongoing divergence from the subtype C consensus. 144 However, correction for false discovery rate (FDR) with a Benjamini Hochberg correction revealed 145 that this divergence was not significant. Divergence from these ancestral sequences is likely enabled 146 by recombination, which unlinks hyper-variable loci from strongly constrained neighbouring sites. 147 We found no evidence for reversions and were therefore unable to conclude that these patients are reverting to founder as described in previous literature^{9,29}. 148

149

To assess the relationship of the observed divergence patterns, we examined nucleotide diversity by considering all pairwise nucleotide distances of each consensus sequence, by timepoint and patient utilizing multidimensional scaling³⁰. Intra-patient nucleotide diversity varied considerably between patients (**Figure 2a**). Viruses from some patients showed little diversity between timepoints (e.g.

patient 16207), whereas those from others showed higher diversity between timepoints (e.g. patient
22763). In some instances, a patient's viruses were tightly clustered suggesting little change over
time (Figure 3A, patients 16207, 26892 & 47939) compared to others (patients 22828 & 28545). To
corroborate the MDS approach, we used an alternative novel method of examining nucleotide
diversity of longitudinal timepoints using all positional information from BAM files (Supplementary
Figure 2).

160

161 **Phylogenetic analysis of inferred haplotypes**

The preceding diversity assessments suggested the existence of distinct viral haplotypes within each patient. We therefore used a recently reported computational tool HaROLD³¹ to infer 289 unique haplotypes across all patients, with between 11 and 32 haplotypes (average 21) per patient. The number haplotypes changed dynamically between successive timepoints indicative of dynamically shifting populations (**Figure 2B**). To confirm plausibility of haplotypes, a phylogeny of all consensus sequences was inferred (**Supplementary Figure 3**) and a MDS plot of all viral haplotypes was constructed (**Supplementary Figure 4**).

169

170 Linkage Disequilibrium and Recombination

LD between two pairwise loci is reduced by recombination, such that LD tends to be higher for loci 171 that are close and lower for more distant loci³². HIV-1 is known to recombine such that sequences 172 are not generally in linkage disequilibrium (LD) beyond 400bp⁹. The significance of recombination in 173 an intra-host, chronic infection setting is less well understood³³. To assess whether intra-patient 174 175 recombination was occurring between the haplotypes observed in each of the three most sampled 176 patients, we determined LD decay patterns. We assumed that if there was random recombination. 177 this would equate to smooth LD decay patterns. This was not observed. Rather, each patient 178 demonstrated a complex decay pattern, consistent with non-random recombination along the 179 genome (Figure 3A). Given this, we characterised recombination patterns (Figure 3B). Inferred 180 recombination breakpoints were identified within patients over successive timepoints 181 (Supplementary Figure 5). DRMs accumulated over successive timepoints for patient 22763, 182 whereas in patient 15664 the reverse was true. Patient 16207 had recombinant breakpoints 183 localised in the pol gene in two timepoints, though it retained its majority DRM (K103N) across all 184 haplotype populations, possibly as a result of K103N being acquired as a transmitted DRM, or as all 185 variants were under the same selective pressure.

186

187 Changing landscapes of non-synonymous and synonymous mutations

188 In the absence of major PI mutations, we first examined non-synonymous mutations across the 189 whole genome (Figures 4-6), with a specific focus on pol (to identify known first and second line 190 NRTI-associated mutations) and gag (given its known involvement in PI susceptibility). We and 191 others have previously shown that gag mutations accumulate during non-suppressive PI therapy^{34,35}. There are also data suggesting associations between *env* mutations and PI exposure ^{36,37}. 192 193 Supplementary Tables 1-3 summarise the changes in variant frequencies of gag, pol and env 194 mutations in patients over time. We found between two and four mutations at sites previously 195 associated with PI resistance in each patient, all at persistently high frequencies (>90%) even in the 196 absence of presumed drug pressure. This is explained by the fact that a significant proportion of sites associated with PI exposure are also polymorphic across HIV-1 subtypes^{20,38}. To complement 197 198 this analysis, we examined underlying synonymous mutations across the genome. This revealed 199 complex changes in the frequencies of multiple nucleotide residues across all genes. These changes 200 often formed distinct 'chevron-like' pattens between timepoints (Figures 4C & 5B), indicative of 201 linked alleles dynamically shifting, which is in turn suggestive of competition between viral 202 haplotypes.

203

Three patients (15664, 16207 and 22763) which had the greatest number of timepoints for ongoing
comparison, and had the highest read coverage, were selected for in-depth viral dynamics analysis
as discussed below.

207

208 Patient 15664 had consistently low plasma concentrations of all drugs at each measured timepoint, 209 with detectable levels measured only at month 15 and beyond (Figure 4A). At baseline, whilst on NNRTI-based 1st-line ART, known NRTI (M184V) and NNRTI (K103N and P225H) DRMs⁵ were at high 210 211 prevalence in the virus populations; which is as expected whilst adhering to 1st-line treatments. 212 Haplotype reconstruction and subsequent analysis inferred the presence of a majority haplotype carrying all three of these mutations at baseline, as well as a minority haplotype with the absence of 213 214 P225H (Figure 4D, dark grey circles). Following the switch to a 2nd-line regimen, variant frequencies 215 of M184V and P225H dropped below detection limits (<2% of reads), whilst K103N remained at high 216 frequency (Figure 4B). Haplotype analysis was concordant, revealing that viruses with K103N, 217 M184V and P225H were replaced by haplotypes with only K103N (Figure 4D, light grey circles). At 218 timepoint two (month 8), there were also numerous synonymous mutations observed at high frequency in both *aga* and *pol* genes, corresponding with the switch to a 2nd-line regimen. At 219 timepoint three (15 months post-switch to 2nd-line regimen) drug concentrations were highest, 220 221 though still low in absolute terms, indicating poor adherence. Between timepoints three and four we

222 observed a two-log reduction in viral load, with a modest change in frequency of RT DRMs. However, 223 we observed synonymous variant frequency shifts predominantly in both gag and pol genes, as 224 indicated by multiple variants increasing and decreasing contemporaneously, creating characteristic 225 chevron patterning (Figure 4B). However, many of the changes were between intermediate 226 frequencies, (e.g. between 20% and 60%), which differed from changes between time points one 227 and two where multiple variants changed more dramatically in frequency from <5% to more than 228 80%, indicating harder selective sweeps. These data are in keeping with a soft selective sweep 229 between time points three and five. Between timepoints five and six, the final two samples, there 230 was another population shift - M184V and P225H frequencies fell below the detection limit at 231 timepoint six, whereas the frequency of K103N dropped from almost 100% to around 80% (Figure 232 4B). This was consistent with the haplotype reconstruction, which inferred a dominant viral 233 haplotype at timepoint six bearing only K103N, as well as three minor haplotype with no DRMs at all 234 (Figure 4D, light blue circles).

235

236 The phylogeny of inferred haplotype sequences showed that haplotypes from all timepoints were 237 interspersed throughout the tree (except at timepoint 4, which remained phylogenetically distinct). 238 DRMs showed some segregation by clade; viruses carrying a higher frequency of DRMs (M184V, 239 P225H and K238T) were observed in clade A (Figure 4D), and those with either K103N alone, or no 240 DRMs were preferentially located clade C (Figure 4D). However, this relationship was not clear cut, 241 and therefore consistent with competition between haplotypes during low drug exposure. Soft 242 sweeps were evident, given the increasing diversity (Figure 1, Supplementary Figure 4) of this 243 patient.

244

245 Patient 16207. Viral load in this patient were consistently above 10,000 copies/ml (Figure 5A). As 246 with patient 15664, detectable drug concentrations in blood plasma were either extremely low or 247 absent at each measured timepoint, consistent with non-adherence to the prescribed regimen. 248 There was little change in the frequency of DRMs throughout the follow-up period, even when making the switch to the 2nd-line regimen. NNRTI resistance mutations such as K103N are known to 249 have minimal fitness costs²⁶ and can therefore persist in the absence of NNRTI pressure. Throughout 250 251 treatment the viruses from this patient maintained K103N at a frequency of >85% but also carried an 252 integrase strand transfer inhibitor (INSTI) associated mutation (E157Q) and PI-exposure associated 253 amino acid replacements (L23I and M46I) at low frequencies at timepoints two and three. Despite 254 little change in DRM site frequencies, very significant viral population shifts were observed at the 255 whole genome level; again indicative of selective sweeps (Figures 5B-C). Between timepoints one

and four, several linked mutations changed abundance contemporaneously, generating chevron-like patterns of non-synonymous changes in *env* specifically (blue lines, **Figure 5B**). A large number of alleles increased in frequency from <40% to >80% at timepoint one, followed by decreases in frequency from >70% to <30% at timepoint three. Whereas large shifts in *gag* and *pol* alleles also occurred, the mutations involved were almost exclusively synonymous (red and green lines).

261

Phylogenetic analysis of inferred whole genome haplotypes again showed a distinct cladal structure as observed in patient 15664 (**Figure 5D**), although the dominant haplotypes were equally observed in the upper clade (A) and lower clade (C) (**Figure 5D**). K103N was the majority DRM at all timepoints, except for a minority haplotype at timepoint three, also carrying E157Q. Haplotypes did not cluster by time point. Significant diversity in haplotypes from this patient was confirmed by MDS (**Supplementary Figure 4**).

268

269 Patient 22763 was notable for a number of large shifts in variant frequencies across multiple drug 270 resistance associated residues and synonymous sites. Drug plasma concentration for different drugs 271 was variable yet detectable at most measured timepoints. This suggests that the patient took some 272 of their prescribed drugs throughout the follow-up period (Figure 6A). Non-PI DRMs such as M184V, 273 P225H and K103N were present at baseline (time of switch from first to second line treatments). 274 These mutations persisted despite synonymous changes between time points one and two. Most of 275 the highly variable synonymous changes in this patient were found in the gag and pol genes (as in 276 patient 16207) (Figure 6C), but in this case env displayed large fluctuations in synonymous and non-277 synonymous allelic frequencies over time. At timepoint three, therapeutic concentrations of boosted 278 lopinavir (LPV/r) and tenofovir (TDF) were measured in plasma and haplotypes clustered separately 279 from the first two timepoints (Figure 6D, light and dark grey circles). NGS confirmed that the D67N, 280 K219Q, K65R, L70R, M184V DRMs and NNRTI-resistance mutations were present at low frequencies 281 from timepoint three onwards. Of note, between timepoints three and six, therapeutic 282 concentrations of TDF were detectable, and coincided with increased frequencies of the canonical 283 TDF DRM, K65R³. The viruses carrying K65R outcompeted those carrying the thymidine analogue 284 mutants (TAMs) D67N and K70R, whilst the lamivudine (3TC) associated resistance mutation, 285 M184V, persisted throughout. In the final three timepoints M46I emerged in *protease*, but never 286 increased in frequency above 6%. At timepoint seven, populations shifted again with some 287 haplotypes resembling those previously seen in timepoint four, with D67N and K70R again being 288 predominant over K65R in reverse transcriptase (Figure 6D, green and blue circles). At the final

timepoint (eight) the frequency of K103N was approximately 85% and the TAM-bearing populations
continued to dominate over the K65R population, which at this timepoint had a low frequency.

291

292 Although the DRM profile suggested the possibility of a selective sweep, we observed the same 293 groups of other non-synonymous or synonymous alleles exhibiting dramatic frequency shifts, but to 294 a lesser degree than in patients 16207 and 15664 i.e. 'chevron patterns' were less pronounced, 295 outside of the env gene (Figure 6B-C). Variable drug pressures placed on the viral populations throughout the 2nd-line regimen appear to have played some role in limiting haplotype diversity. 296 297 Timepoints 1-4 all formed distinct clades, without intermingling, indicating that competition 298 between populations was not occurring to the same degree as in previous patients. Some inferred 299 haplotypes had K65R and others the TAMs D67N and K70R. K65R was not observed in combination 300 with D67N or K70R, consistent with previously reported antagonism between K65R and TAMs 301 whereby these mutations are not commonly found together within a single genome³⁹⁻⁴¹. One 302 explanation for the disconnect between the trajectories of DRM frequencies over time and 303 haplotype phylogeny is competition between different viral populations. Alternatively, emergence of 304 haplotypes from previously unsampled reservoirs with different DRM profiles is possible, but one 305 might have expected other mutations to characterise such haplotypes that would manifest as 306 changes in the frequencies of large numbers of other mutations.

307

308 Discussion

309 The proportion of people living with HIV (PLWH) who are accessing ART has increased from 24% in 2010, to 68% in 2020^{42,43}. However, with the scale-up of ART, there has also been an increase in both 310 pre-treatment drug resistance (PDR)^{44,45} and acquired drug resistance^{14,46} to 1st-line ART regimens 311 312 containing NNRTIs. Integrase inhibitors (specifically dolutegravir) are now recommended for first-313 line regimens by the WHO in regions where PDR exceeds 10%⁴⁷. Boosted PI-containing regimens remain second line drugs following first 1st-line failure, though one unanswered question relates to 314 315 the nature of viral populations during failure on PI-based ART where major mutations in protease, 316 described largely for less potent PIs, have not emerged. Here we have comprehensively analysed 317 viral populations present in longitudinally collected plasma samples of chronically infected HIV-1 patients under non-suppressive 2nd-line ART. 318

319

With the vast majority of PLWH ho have been treated in the post-ART era, virus dynamics during non-suppressive ART are important to understand, as there may be implications for future therapeutic success. For example, broadly neutralising antibodies (bNab) are being tested not only

for prevention, but also as part of remission strategies in combination with latency reversal agents. We know that HIV sensitivity to broadly neutralising antibodies (bNab) is dependent on *env* diversity^{48,49}, and therefore prolonged ART failure with viral diversification could compromise sensitivity to these agents.

327

328 Our understanding of virus dynamics largely stems from studies that were limited to untreated individuals¹², with mostly subgenomic data analysed rather than whole genomes¹². Traditional 329 analyses of quasispecies distributions, for example as reported by Yu et al⁵⁰, suggest that viral 330 331 diversity increases in longitudinal samples. However, the findings of Yu et al were based entirely on 332 short-read NGS data without considering whole-genome haplotypes. The added benefit of 333 examining whole genomes is that linked mutations can be identified statistically using an approach that we recently developed³¹. Indeed, haplotype reconstruction has proved beneficial in the analysis 334 335 of compartmentalisation and diversification of several RNA and DNA viruses, including HIV-1, CMV and SARS-CoV-2^{34,51,52}. 336

337

338 Key findings of this study were, firstly that diversity as defined by the number of quasispecies in each 339 sample, typically increased over time. Considering divergence, (a measure at consensus level for 340 how many mutations have accumulated in a current sequence, from the founder infection) in 341 contrast to previous literature which showed that there was a degree of reversion to the founder 342 strain⁹, we show that there was no significant reversion in our study population. There was also no 343 significant divergence from baseline or ancestral C consensus sequences when considering the 344 whole genome. However, when considering 1000bp fragments of the genome in a sliding window, 345 several regions in *pol*, *vpu* and *env* significantly diverged from the consensus C sequence.

346

347 A second key finding in our study was that synonymous mutations were generally two-to-three fold 348 more frequent than non-synonymous mutations during non-suppressive ART during chronic infection - a finding in contrast to that seen previously in a longitudinal study of untreated 349 individuals^{2,12,50}. Non-synonymous changes were enriched in known polymorphic regions such as *env* 350 351 whereas synonymous changes were more often observed to fluctuate in the conserved pol gene. This finding may reflect early versus chronic infection and differing selective pressures. Haplotype 352 353 reconstruction revealed evidence for competing haplotypes, with phylogenetic evidence for 354 numerous soft selective sweeps in that haplotypes intermingled during periods where there were 355 low drug concentrations measured in the blood plasmas of patients. Non-adherence to drug 356 regimens therefore offers opportunity for the HIV-1 reservoir to increase in size and is associated

with higher levels of residual viraemia⁵³, preventing future viral suppression due to accumulation
and maintenance of beneficial mutations.

359

360 Individuals in the present study were treated with Ritonavir-boosted Lopinavir along with two NRTIs 361 (typically Tenofovir + Emtricitabine). We observed significant changes in the frequencies of NRTI 362 mutations in two of the three patients studied in-depth. We saw evidence for possible archived virus 363 populations with DRMs emerging during follow-up in that large changes in DRM frequency were not 364 always accompanied by changes at other sites. This is consistent both with the occurrence of soft 365 selective sweeps and previous observations that non-DRMs do not necessarily drift with other mutations to fixation²³. As frequencies of RT DRMs did not always segregate with haplotype 366 367 frequencies (i.e. the same mutations were repeatedly observed on different genetic backgrounds), 368 we suggest that a high number of recombination events, known to be common in HIV infections, 369 were likely contributing to the observed haplotypic diversity.

370

371 Although no patient developed major resistance mutations to PIs at consistently high frequencies 372 (https://hivdb.stanford.edu/dr-summary/resistance-notes/PI/), we did observe non-synonymous 373 mutations in *gag* which have been previously associated to mediate resistance to PI. There was, 374 however, no temporal evidence of specific mutations being associated with selective sweeps. For 375 example, PI exposure-associated residues in matrix (positions 76 and 81) were observed in patient 16207 prior to PI initiation⁵⁴. Furthermore, patient 16207 was one of two patients who achieved 376 377 low-level viraemic suppression (45-999 copies/ml) of viral replication at one or two timepoints. After 378 both of these partial suppressions, the rebound populations appeared to be less diverse, consistent 379 with drug-resistant viruses re-emerging.

380

381 Mutations at sites in the HIV genome that are further apart than 100bp are subject to frequent shuffling via recombination⁵⁵. Unlike the smooth LD decay curves for pairs of HIV mutations reported 382 383 in the literature, we identified complex LD decay patterns within the genomes of viruses from 384 individual patients: patterns indicative of non-random recombination. Recombination appears as the 385 loss and gain of common genomic regions over successive timepoints between each patient's 386 haplotype populations (Figure 3B). Viruses from patient 15664 with inter-haplotype recombination 387 events detectable in the vif and vpr genes were present at four of the six analysed timepoints. In 388 contrast, viruses in patient 22763 had evidence of inter-haplotype recombination events in the gag-389 pol genes were present at three of the eight analysed timepoints. We explain these recombination 390 events detectable in longitudinally sampled sequences, as reflected in the previously discussed

391 'chevron' patterns whereby variants increase and subsequently decrease between timepoints. HIV 392 quasispecies foster a degree of genetic diversity that facilitate rapid adaptive evolution through 393 recombination whenever there exists within the guasispecies combinations of mutations that 394 provide fitness advantages⁸. The relationship between recombination and the accumulation of 395 multiple DRMs within individual genomes is not clearly evident within the analysed sequence 396 datasets, with viruses sampled from each patient showing unique patterns of recombination. Inter-397 haplotype recombinants detected at timepoints two and six in patient 16207 had recombination 398 events in pol that involved the transfer of the major DRM, K103N. Three independent Inter-399 haplotype recombination events detected in *pol* of patient 22763 viruses at timepoints two, four and 400 six resulted in no change in DRMS at timepoint two, the gain of DRMS at timepoint four and loss of 401 DRMs at timepoint six. The recombination dynamics in this patient were occurring against a 402 backdrop of apparent antagonism between TAMs and DRMs (K65R and D67N). Finally, patient 15664 403 steadily lost DRMs throughout the longitudinal sampling period, although we found no evidence of 404 recombination being implicated in this loss. This suggests that, in the absence of strong drug 405 pressures, viral populations only maintained DRMs which were crucial for providing resistance to 406 drugs that the patient was variably adhering to at the time.

407

408 Phylogenetic analyses of whole genome viral haplotypes demonstrated two common features: (1) 409 evidence for selective sweeps following therapy switches or large changes in plasma drug 410 concentrations, with hitchhiking of synonymous and non-synonymous mutations; and (2) 411 competition between multiple viral haplotypes that intermingled phylogenetically alongside soft 412 selective sweeps. The diversity of viral populations was maintained between successive timepoints 413 with ongoing viremia, particularly in *env*. Changes in haplotype dominance were often distinct from 414 the dynamics of drug resistance mutations in reverse transcriptase (RT), indicating the presence of 415 softer selective sweeps and/or recombination.

416

417 This study had some limitations – we examined eight patients with ongoing viraemia and variable adherence to 2nd-line drug regimens, with three of these being examined in-depth. Despite the small 418 419 sample size, this type of longitudinal sampling of ART-experienced patients is unprecedented. We 420 are confident that the combination of computational analyses has provided a detailed 421 understanding of viral dynamics under non-suppressive ART that will be applicable to wider 422 datasets. The method used to reconstruct viral haplotypes in silico is novel and has previously been validated in HIV-1 positive patients coinfected with CMV⁵¹. We are confident that the approach 423 424 implemented by HaROLD has accurately, if conservatively, estimated haplotype frequencies and

future studies should look to validate these frequencies using an *in vitro* method such as singlegenome amplification.

427

428 Despite there being high viral loads present at each of the analysed timepoints, nuances of the 429 sequencing method resulted in suboptimal gene coverage, particularly in the env gene. To ensure 430 that uneven sequencing coverage did not bias our analyses, we ensured that variant analysis was 431 only performed where coverage was >100 reads. We also utilised a second method of haplotype 432 reconstruction, in order to determine concordance of DRM calls between the two methods used. 433 We find that there was good concordance between the two methods, specifically highlighted by the 434 antagonism between TAMs (D67N and K70R) and NRTI mutations (K65R) in patient 22763 435 (Supplementary Figures 6).

436

437 In summary we have found compelling evidence of HIV-1 within-host viral diversification, 438 recombination and haplotype competition during non-suppressive ART. In future patients failing PI-439 based regimens are likely to be switched to INSTI-based ART (specifically Dolutegravir in South 440 Africa) prior to genotypic typing or resistance analysis. Although the prevalence of underlying major INSTI resistance mutations is low in sub-Saharan Africa^{56,57}, data linking individuals with NNRTI 441 resistance with poorer virological outcomes on Dolutegravir⁵⁸, coupled with a history of intermittent 442 443 adherence, warrant further investigation. Having shown that long-time intra-host PI failure increases 444 the intra-patient diversity of HIV viral populations, monitoring future drug-failure cases will be of 445 interest due to their capacity to maintain a reservoir of transmissible drug-resistant viruses, as well 446 as impacting responses to future therapies.

447

448

449 Methods

450 Study & Patient selection

451 This cohort was nested within the French ANRS 12249 Treatment as Prevention (TasP) trial ²⁷. TasP 452 was a cluster-randomised trial comparing an intervention arm which offered ART after HIV diagnosis 453 irrespective of patient CD4 + count, to a control arm offering ART according to prevailing South 454 African guidelines. In total, a subset of 44 longitudinal samples from eight chronically infected patients with virological failure of 2nd-line PI-based ART, with viraemia above 1000 copies/ml were 455 456 analysed. From these eight patients, three patients with mean coverage of >2000 reads across the 457 whole genome were selected from in-depth viral dynamic analysis. All samples were collected from blood plasma. The Illumina MiSeg platform was used and an adapted protocol for sequencing⁵⁹. 458

Adherence to 2nd-line regimens was measured by high-performance liquid chromatography (HPLC) using plasma concentration of drug levels as a proxy. Drug levels were measured at each timepoint with detectable viral loads, post-PI initiation. Cut-offs for assessment of adherence were selected from published literature.

463

Ethical approval was originally grant by the Biomedical Research Ethics Committee (BFC 104/11) at the University of KwaZulu-Natal, and the Medicines Control Council of South Africa for the TasP trial (Clinicaltrials.gov: <u>NCT01509508</u>; South African Trial Register: DOH-27-0512-3974). The study was also authorized by the KwaZulu-Natal Department of Health in South Africa. Written informed consent was obtained from all patients. Original ethical approval also included downstream sequencing of blood plasma samples and analysis of those sequences to better understand drug resistance. No additional ethical approval was required for this.

471

472 Illumina Sequencing

Sequencing of viral RNA was performed as previously described by Derache et al ⁶⁰ using a modified protocol previously described by Gall et al ⁶¹. Briefly, RNA was extracted from 1ml of plasma with detectable viral load of >1000 copies/ml, using QIAamp Viral RNA mini kits (Qiagen, Hilden, Germany), and eluted in 60µl of elution buffer. The near-full HIV genome was amplified with four HIV-1 subtype C primer pairs, generating 4 overlapping amplicons of between 2100 and 3900kb.

478

DNA concentrations of amplicons were quantified with the Qubit dsDNA HS Assay kit (Invitrogen,
Carlsbad, CA). Diluted amplicons were pooled equimolarly and prepared for library using the Nextera
XT DNA Library preparation and the Nextera XT DNA sample preparation index kits (Illumina, San
Diego, CA), following the manufacturer's protocol.

483

484 Genomics & Bioinformatics

Poor quality reads (with Phred score <30) and adapter sequences were trimmed from FastQ files 485 with TrimGalore! v0.6.519⁶² and mapped to a dual-tropic, clade C, south African reference genome 486 (AF411967) with minimap2⁶³. The reference genome was manually annotated in Geneious Prime 487 v2020.3 with DRMs according to the Stanford HivDB 64 . Optical PCR duplicate reads were removed 488 489 using Picard tools (http://broadinstitute.github.io/picard). Finally, QualiMap2⁶⁵ was used to assess 490 the mean mapping quality scores and coverage in relation to the reference genome for the purpose of excluding poorly mapped sequences from further analysis. Single nucleotides polymorphisms 491 (SNPs) were called using VarScan 2^{66} with a minimum average quality of 20, minimum variant 492

493 frequency of 2% and in at least 100 reads. These were then annotated by gene, codon and amino
 494 acid alterations using an in-house script⁶⁷ modified to utilise HIV genomes.

495

All synonymous and non-synonymous variants (including DRMs) were examined, and their frequency compared across successive timepoints. Synonymous variants were excluded from analysis if their prevalence remained at $\leq 10\%$ or $\geq 90\%$ across all timepoints. DRMs were retained for analysis if they were present at over 2% frequency and on at least two reads. A threshold of 2% is supported by a study evaluating different analysis pipelines, which reported fewer discordances over this cut-off ⁶⁸.

501

502 Measuring Divergence or Reversion to Baseline & Consensus C Ancestor

For each patient divergence over time from inferred founder state was measured for 1) the baseline sequence for each patient; and 2) a reconstructed subtype C consensus. The full length HIV-1 subtype C consensus was downloaded from the LANL HIV database and annotations from the subtype C reference sequence (AF411967.3) used for haplotype reconstruction were transferred to this genome using Geneious Prime v2021.1.0 to ensure positions remained consistent throughout.

508

509 Divergence was measured as the pairwise distance between timepoint consensus and founder, 510 calculated using the dist.dna() package with a TN93 nucleotide-nucleotide substitution matrix and 511 with pairwise deletion as implemented in the R package Ape v.5.4.

512

513 Linear Mixed Effects Models

To investigate the general relationship of time in months to divergence, incorporating all 8 patients, we built a series of Linear Mixed Effect Models implemented in the Imer R package. Divergence was treated as the response, time as a fixed effect and patient as a random effect. We built similar models for the whole genome & discrete genomic portions analysis, for each founder strain. We tested if time had a non-0 effect on divergence by calculating p-value using Satterthwaite's method as implemented in the ImerTEst package. For the 1000bp analyses, a Benjamini Hochberg correction adjustment was undertaken to account for 9 tests within the same sample.

521

522 Haplotype Reconstruction & Phylogenetics

523 Whole-genome viral haplotypes were constructed for each patient timepoint using HaROLD 524 (Haplotype Reconstruction for Longitudinal Samples)³¹. The first stage consists of SNPs being 525 assigned to each haplotype such that the frequency of variants is equal to the sum of the 526 frequencies of haplotypes containing a specific variant. This considers the frequency of haplotypes in

527 each sample, the base found at each position in each haplotype and the probability of erroneous 528 measurements at that site. Maximal log likelihood was used to optimise time-dependent 529 frequencies for longitudinal haplotypes which was calculated by summing over all possible 530 assignment of haplotype variants. Haplotypes were then constructed based on posterior 531 probabilities.

532

After constructing haplotypes, a 2nd stage or refinement process remaps reads from BAM files to 533 constructed haplotypes. This begins with the *a posteriori* probability of each base occurring at each 534 535 site in each haplotype from the first stage, but relaxes the assumption that haplotypes are identical 536 at each sample timepoint and instead uses variant co-localisation to refine haplotype predictions. 537 Starting with the estimated frequency of each haplotype in a sample, haplotypes are optimised by 538 probabilistically assigning reads to the various haplotypes. Reads are then reassigned iteratively until 539 haplotype frequencies converge. The number of haplotypes either increases or decreases as a result 540 of combination or division according to AIC scores, in order to present the most accurate 541 representation of viral populations at each timepoint.

542

543 Whole-genome nucleotide diversity was calculated from BAM files using an in-house script 544 (<u>https://github.com/ucl-pathgenomics/NucleotideDiversity</u>). Briefly diversity is calculated by fitting 545 all observed variant frequencies to either a beta distribution or four-dimensional Dirichlet 546 distribution plus delta function (representing invariant sites). These parameters were optimised by 547 maximum log likelihood.

548

549 Maximum-likelihood phylogenetic trees and ancestral reconstruction were performed using IQTree2 550 v2.1.3⁶⁹ and a GTR+F+I model with 1000 ultrafast bootstrap replicates⁷⁰. All trees were visualised 551 with Figtree v.1.4.4 (http://tree. bio.ed.ac.uk/software/figtree/), rooted on the AF411967.3 552 reference sequence, and nodes arranged in descending order. Phylogenies were manipulated and 553 annotated using ggtrree v2.2.4.

554

Additionally, as a sensitivity analysis, clique-snv⁷¹ was used to infer a second set of haplotypes using the following flags: -m snv-illumina -fdf extended4 -threads 20 -cm accurate. This was to determine concordance of drug resistance mutation calls within haplotypes.

558

559 Multi Dimension Scaling (MDS) Plots

560 Pairwise distances between these consensus sequences were calculated using the dist.dna() 561 package, with a TN93 nucleotide-nucleotide substitution matrix and with pairwise deletion 562 implemented in the R package Ape v.5.4. Non-metric Multi-dimensional scaling (MDS) was 563 implemented using the metaMDS() function in the R package, vegan v2.5.7. MDS is a method to 564 attempt to simplify high dimensional data into a simpler representation of reducing dimensionality 565 whilst retaining most of the variation relationships between points. We find that like network trees, 566 non-metric MDS better represents the true relative distances between sequences, whereas 567 eigenvector methods are less reliable in this sense. In a genomics context we can apply 568 dimensionality reduction on pairwise distance matrices, where each dimension is a sequence with 569 data points of n-1 sequences pairwise distance. The process was repeated with whole genome 570 haplotype sequences.

571

572 Linkage Disequilibrium & Recombination

Starting with a sequence alignment we determined the pairwise LD r^2 associations for all variable sites using WeightedLD ⁷² without weighting. This method allowed us to exclude sites with any insertions or ambiguous characters easily where we used the option --min-acgt 0.99 and --minvariability 0.05. The pairwise R² values were then binned per 200bp comparison distance blocks along the genome and the mean R² value were taken and represented graphically to assess LD decay. This analysis was run for the three patients taken forward for in-depth analysis and run using an alignment of all their timepoint samples. Graphics were generated using Rv4.04.

580

We first performed an analysis for detecting individual recombination events in individual genome sequences using the RDP, GENECONV, BOOTSCAN, MAXCHI, CHIMAERA, SISCAN, and 3SEQ methods implemented in RDP5⁷³ with default settings. Putative breakpoint sites were identified and manually checked and adjusted if necessary using the BURT method with the MAXCHI matrix and LARD two breakpoint scan methods. Final recombination breakpoint sites were confirmed if at least three or more methods supported the existence of the recombination breakpoint.

587

588 Funding

589 SAK is supported by the Bill and Melinda Gates Foundation: OPP1175094. RKG is supported by 590 Wellcome Trust Senior Fellowship in Clinical Science: WT108082AIA. OC is supported by a PhD 591 studentship/UKRI MRC grant: MR/N013867/1. DPM is funded by The Wellcome Trust 592 (222574/Z/21/Z).

593

594 Competing Interests

- 595 RKG has received ad hoc consulting fees from Gilead, ViiV and UMOVIS Lab.
- 596

597 Author Contributions

- 598 Conceptualization: S.A.K, D.P, R.K.G., R.G; Preparation of genomic data: S.A.K, A.D, O.J.C, W.S;
- 599 Recombination Analysis: S.A.K, O.J.C, D.M; Haplotype Reconstruction: S.A.K, O.J.C, R.G, W.S; writing
- original draft preparation, S.A.K, O.J.C, R.K.G; writing review and editing: all authors.
- 601

602 Data Availability Statement

- All bam files used to undertake analyses have been deposited on the SRA database with the
 following accession numbers SRR15510046 SRR15510072.
- 605

606 Code Availability Statement

607 Custom code used to produce figures and graphs can be found at: <u>https://github.com/Steven-</u>
608 Kemp/21-2 hiv tasp/tree/main/scripts.

609

610 Acknowledgements

611 The TasP trial was sponsored by the French National Agency for AIDS and Viral Hepatitis Research 612 (ANRS; grant number, 2011-375), and funded by the ANRS, the Deutsche Gesellschaft für 613 Internationale Zusammenarbeit (GIZ; grant number, 81151938), and the Bill & Melinda Gates 614 Foundation through the 3ie Initiative. This trial was supported by Merck and Gilead Sciences, which 615 provided the Atripla drug supply. The Africa Health Research Institute, (previously Africa Centre for 616 Population Health, University of KwaZulu-Natal, South Africa) receives core funding from the 617 Wellcome Trust, which provided the platform for the population-based and clinic-based research at 618 the centre. We thank Alpha Diallo and Severine Gibowski at the ANRS for pharmacovigilance 619 support, and Jean-François Delfraissy (director of ANRS). We thank the study volunteers for allowing 620 us into their homes and participating in this trial, and the KwaZulu-Natal Provincial and the National 621 Department of Health of South Africa for their support of this study. We thank staff of the Africa 622 Health Research Institute for the trial implementation and analysis of data, including those who did 623 the fieldwork, provided clinical care, developed and maintained the database, entered the data, and 624 verified data quality.

625

626 References

- 6271Abrahams, M. R. et al. Quantitating the multiplicity of infection with human628immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted629variants. J Virol 83, 3556-3567, doi:10.1128/JVI.02132-08 (2009).
- 6302Zanini, F., Puller, V., Brodin, J., Albert, J. & Neher, R. A. In vivo mutation rates and the631landscape of fitness costs of HIV-1. Virus Evol 3, vex003, doi:10.1093/ve/vex003 (2017).
- 6323Salemi, M. The intra-host evolutionary and population dynamics of human633immunodeficiency virus type 1: a phylogenetic perspective. Infect Dis Rep 5, e3,634doi:10.4081/idr.2013.s1.e3 (2013).
- Lemey, P., Rambaut, A. & Pybus, O. G. HIV evolutionary dynamics within and among hosts. *Aids Reviews* 8, 125-140 (2006).
- 6375Collier, D. A., Monit, C. & Gupta, R. K. The Impact of HIV-1 Drug Escape on the Global638Treatment Landscape. Cell host & microbe 26, 48-60, doi:10.1016/j.chom.2019.06.010639(2019).
- 640 6 Biebricher, C. K. & Eigen, M. What is a quasispecies? *Curr Top Microbiol Immunol* 299, 1-31,
 641 doi:10.1007/3-540-26397-7_1 (2006).
- Wilke, C. O. Quasispecies theory in the context of population genetics. *BMC Evol Biol* 5, 44, doi:10.1186/1471-2148-5-44 (2005).
- Lauring, A. S. & Andino, R. Quasispecies theory and the behavior of RNA viruses. *PLoS Pathog* 6, e1001005, doi:10.1371/journal.ppat.1001005 (2010).
- 646 9 Zanini, F. *et al.* Population genomics of intrapatient HIV-1 evolution. *Elife* 4, e11282,
 647 doi:10.7554/eLife.11282 (2015).
- Lythgoe, K. A. & Fraser, C. New insights into the evolutionary rate of HIV-1 at the within-host
 and epidemiological levels. *Proceedings of the Royal Society B-Biological Sciences* 279, 33673375, doi:10.1098/rspb.2012.0595 (2012).
- 65111Hedskog, C. et al. Dynamics of HIV-1 Quasispecies during Antiviral Treatment Dissected652Using Ultra-Deep Pyrosequencing. PloS one 5, e11345, doi:ARTN e11345
- 653 10.1371/journal.pone.0011345 (2010).
- 65412Shankarappa, R. et al. Consistent viral evolutionary changes associated with the progression655of human immunodeficiency virus type 1 infection. J Virol 73, 10489-10502,656doi:10.1128/JVI.73.12.10489-10502.1999 (1999).
- 65713Masikini, P. & Mpondo, B. C. HIV drug resistance mutations following poor adherence in HIV-658infected patient: a case report. Clin Case Rep 3, 353-356, doi:10.1002/ccr3.254 (2015).
- 65914TenoRes Study, G. Global epidemiology of drug resistance after failure of WHO660recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective661cohort study. Lancet Infect Dis 16, 565-575, doi:10.1016/S1473-3099(15)00536-8 (2016).
- 66215Collier, D. et al. Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for663Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A664Competing-Risks Prospective Cohort Analysis. Clinical infectious diseases : an official665publication of the Infectious Diseases Society of America 64, 1006-1016,666doi:10.1093/cid/cix015 (2017).
- 66716Giandhari, J. et al. Genetic Changes in HIV-1 Gag-Protease Associated with Protease668Inhibitor-Based Therapy Failure in Pediatric Patients. AIDS Res Hum Retroviruses **31**, 776-669782, doi:10.1089/AID.2014.0349 (2015).
- Kelly Pillay, S., Singh, U., Singh, A., Gordon, M. & Ndungu, T. Gag drug resistance mutations
 in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with
 detectable lopinavir levels. *Journal of the International AIDS Society* **17**, 19784 (2014).
- 67318Sutherland, K. A. et al. Evidence for Reduced Drug Susceptibility without Emergence of674Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA675Trial. PloS one 10, e0137834, doi:10.1371/journal.pone.0137834 (2015).

- 67619Sutherland, K. A. et al. Phenotypic characterization of virological failure following677lopinavir/ritonavir monotherapy using full-length Gag-protease genes. The Journal of678antimicrobial chemotherapy 69, 3340-3348, doi:10.1093/jac/dku296 (2014).
- Sutherland, K. A. *et al.* Gag-Protease Sequence Evolution Following Protease Inhibitor
 Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa. *AIDS research and human retroviruses* **31**, 1032-1037, doi:10.1089/aid.2015.0138 (2015).
- 68221Day, C. L. et al. Proliferative capacity of epitope-specific CD8 T-cell responses is inversely683related to viral load in chronic human immunodeficiency virus type 1 infection. Journal of684virology 81, 434-438, doi:10.1128/JVI.01754-06 (2007).
- Blanch-Lombarte, O. *et al.* HIV-1 Gag mutations alone are sufficient to reduce darunavir
 susceptibility during virological failure to boosted PI therapy. *The Journal of antimicrobial chemotherapy* **75**, 2535-2546, doi:10.1093/jac/dkaa228 (2020).
- Feder, A. F. *et al.* More effective drugs lead to harder selective sweeps in the evolution of
 drug resistance in HIV-1. *Elife* 5, e10670, doi:10.7554/eLife.10670 (2016).
- Harris, R. B., Sackman, A. & Jensen, J. D. On the unfounded enthusiasm for soft selective
 sweeps II: Examining recent evidence from humans, flies, and viruses. *PLoS genetics* 14, e1007859, doi:10.1371/journal.pgen.1007859 (2018).
- 69325Dam, E. et al. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in694highly drug-experienced patients besides compensating for fitness loss. PLoS pathogens 5,695e1000345 (2009).
- 69626Cong, M. E., Heneine, W. & Garcia-Lerma, J. G. The fitness cost of mutations associated with697human immunodeficiency virus type 1 drug resistance is modulated by mutational698interactions. Journal of Virology 81, 3037-3041, doi:10.1128/Jvi.02712-06 (2007).
- 69927Iwuji, C. C. et al. Evaluation of the impact of immediate versus WHO recommendations-700guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment701as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a702cluster randomised controlled trial. Trials 14, 230, doi:10.1186/1745-6215-14-230 (2013).
- World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for
 treating and preventing HIV infection: recommendations for a public health approach.
 (World Health Organization, 2016).
- 70629Carlson, J. M. et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission707bottleneck. Science (New York, N.Y.) 345, 1254031-1254031, doi:10.1126/science.1254031708(2014).
- 709 30 Cox, M. A. & Cox, T. F. in Handbook of data visualization 315-347 (Springer, 2008).
- 71031Pang, J. et al. Haplotype assignment of longitudinal viral deep-sequencing data using co-711variation of variant frequencies. bioRxiv, 444877, doi:10.1101/444877 (2020).
- 71232Stephens, M. & Scheet, P. Accounting for Decay of Linkage Disequilibrium in Haplotype713Inference and Missing-Data Imputation. The American Journal of Human Genetics 76, 449-714462, doi:<u>https://doi.org/10.1086/428594</u> (2005).
- 71533Song, H. et al. Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in716natural infection. Nature Communications 9, 1928, doi:10.1038/s41467-018-04217-5 (2018).
- 71734Datir, R. *et al.* In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1718Matrix. *mBio* **11**, e02036-02020, doi:10.1128/mBio.02036-20 (2020).
- 71935Kletenkov, K. et al. Role of Gag mutations in PI resistance in the Swiss HIV cohort study:720bystanders or contributors? J Antimicrob Chemother 72, 866-875, doi:10.1093/jac/dkw493721(2017).
- 72236Rabi, S. A. *et al.* Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics723and resistance. *The Journal of clinical investigation* **123**, 3848-3860, doi:10.1172/JCI67399724(2013).
- 72537Manasa, J. et al. Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease726Inhibitors. Sci Rep 7, 11559, doi:10.1038/s41598-017-11893-8 (2017).

- 72738Datir, R., El Bouzidi, K., Dakum, P., Ndembi, N. & Gupta, R. K. Baseline PI susceptibility by728HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based729second-line ART in Nigeria. The Journal of antimicrobial chemotherapy 74, 1402-1407,730doi:10.1093/jac/dkz005 (2019).
- Parikh, U. M., Zelina, S., Sluis-Cremer, N. & Mellors, J. W. Molecular mechanisms of
 bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse
 transcriptase. *Aids* 21, 1405-1414 (2007).
- 73440Parikh, U. M., Bacheler, L., Koontz, D. & Mellors, J. W. The K65R mutation in human735immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic736antagonism with thymidine analog mutations. Journal of virology 80, 4971-4977 (2006).
- 73741Parikh, U. M., Barnas, D. C., Faruki, H. & Mellors, J. W. Antagonism between the HIV-1738reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic739level. The Journal of infectious diseases 194, 651-660 (2006).
- 740 42 Department of Health. 2019 ART Clinical Guidelines for the Management of HIV in Adults,
 741 Pregnancy, Adolescents, Children, Infants and Neonates. (Republic of South Africa National
 742 Department of Health, 2019).
- 74343UNAIDS.GlobalHIV& AIDSstatistics2020factsheet,744<https://www.unaids.org/en/resources/fact-sheet> (2020), Accessed 3rd March 2021.
- 74544Gupta, R. K. et al. HIV-1 drug resistance before initiation or re-initiation of first-line746antiretroviral therapy in low-income and middle-income countries: a systematic review and747meta-regression analysis. Lancet Infect Dis 18, 346-355, doi:10.1016/S1473-3099(17)30702-7488 (2018).
- 749 45 Gupta, R. K. et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global 750 751 collaborative study and meta-regression analysis. Lancet 380. 1250-1258, 752 doi:10.1016/S0140-6736(12)61038-1 (2012).
- 75346Gregson, J. et al. Occult HIV-1 drug resistance to thymidine analogues following failure of754first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub755Saharan Africa: a retrospective multi-centre cohort study. Lancet Infect Dis,756doi:10.1016/S1473-3099(16)30469-8 (2017).
- 757 47 WHO, C. Global Fund. HIV drug resistance report. 2017. World Health Organisation (2017).
- 75848Stefic, K., Bouvin-Pley, M., Braibant, M. & Barin, F. Impact of HIV-1 Diversity on Its Sensitivity759to Neutralization. Vaccines (Basel) 7, 74, doi:10.3390/vaccines7030074 (2019).
- Pancera, M. *et al.* Structure and immune recognition of trimeric pre-fusion HIV-1 Env. *Nature* 514, 455-461, doi:10.1038/nature13808 (2014).
- 76250Yu, F. et al. The Transmission and Evolution of HIV-1 Quasispecies within One Couple: a763Follow-up Study based on Next-Generation Sequencing. Scientific reports 8, 1404,764doi:10.1038/s41598-018-19783-3 (2018).
- 76551Pang, J. et al. Mixed cytomegalovirus genotypes in HIV-positive mothers show766compartmentalization and distinct patterns of transmission to infants. Elife 9, e63199,767doi:10.7554/eLife.63199 (2020).
- 76852Boshier, F. A. T. *et al.* Remdesivir induced viral RNA and subgenomic RNA suppression, and769evolution of viral variants in SARS-CoV-2 infected patients. *medRxiv*,7702020.2011.2018.20230599, doi:10.1101/2020.11.18.20230599 (2020).
- 77153Li, J. Z. *et al.* Incomplete adherence to antiretroviral therapy is associated with higher levels772of residual HIV-1 viremia. *AIDS* 28, 181-186, doi:10.1097/QAD.00000000000123 (2014).
- 77354Parry, C. M. et al. Three residues in HIV-1 matrix contribute to protease inhibitor774susceptibility and replication capacity. Antimicrobial agents and chemotherapy 55, 1106-7751113, doi:10.1128/AAC.01228-10 (2011).
- 77655Neher, R. A. & Leitner, T. Recombination rate and selection strength in HIV intra-patient777evolution. PLoS Comput Biol 6, e1000660, doi:10.1371/journal.pcbi.1000660 (2010).

56 El Bouzidi, K. *et al.* High prevalence of integrase mutation L74I in West African HIV-1
subtypes prior to integrase inhibitor treatment. *J Antimicrob Chemother* **75**, 1575-1579,
doi:10.1093/jac/dkaa033 (2020).

- 78157Derache, A. *et al.* Predicted antiviral activity of tenofovir versus abacavir in combination with782a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African783patients initiating or failing first-line ART. The Journal of antimicrobial chemotherapy,784doi:10.1093/jac/dky428 (2018).
- 78558Siedner, M. J. et al. Reduced efficacy of HIV-1 integrase inhibitors in patients with drug786resistance mutations in reverse transcriptase. Nat Commun 11, 5922, doi:10.1038/s41467-787020-19801-x (2020).
- 78859Iwuji, C. et al. Universal test and treat is not associated with sub-optimal antiretroviral789therapy adherence in rural South Africa: the ANRS 12249 TasP trial. J Int AIDS Soc 21,790e25112, doi:10.1002/jia2.25112 (2018).
- 79160Derache, A. et al. Impact of Next-generation Sequencing Defined Human Immunodeficiency792Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-793as-Prevention Trial. Clinical infectious diseases : an official publication of the Infectious794Diseases Society of America 69, 207-214, doi:10.1093/cid/ciy881 (2019).
- 79561Gall, A. *et al.* Universal amplification, next-generation sequencing, and assembly of HIV-1796genomes. Journal of clinical microbiology **50**, 3838-3844, doi:10.1128/JCM.01516-12 (2012).
- 79762Martin, M. J. E. j. Cutadapt removes adapter sequences from high-throughput sequencing798reads. 17, pp. 10-12 (2011).
- 79963Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics (Oxford,800England) 34, 3094-3100, doi:10.1093/bioinformatics/bty191 (2018).
- 80164Shafer, R. W. Rationale and uses of a public HIV drug-resistance database. The Journal of802infectious diseases 194 Suppl 1, S51-58, doi:10.1086/505356 (2006).
- 803 65 Okonechnikov, K., Conesa, A. & Garcia-Alcalde, F. Qualimap 2: advanced multi-sample
 804 quality control for high-throughput sequencing data. *Bioinformatics (Oxford, England)* 32,
 805 292-294, doi:10.1093/bioinformatics/btv566 (2016).
- 80666Koboldt, D. C. *et al.* VarScan 2: somatic mutation and copy number alteration discovery in807cancer by exome sequencing. *Genome Res* 22, 568-576, doi:10.1101/gr.129684.111 (2012).
- 80867Charles, O. J., Venturini, C. & Breuer, J. cmvdrg An R package for Human Cytomegalovirus809antiviral Drug Resistance Genotyping. bioRxiv, 2020.2005.2015.097907,810doi:10.1101/2020.05.15.097907 (2020).
- 81168Perrier, M. et al. Evaluation of different analysis pipelines for the detection of HIV-1 minority812resistant variants. PloS one 13, e0198334, doi:10.1371/journal.pone.0198334 (2018).
- 81369Minh, B. Q. et al. IQ-TREE 2: New models and efficient methods for phylogenetic inference in814the genomic era. bioRxiv, 849372, doi:10.1101/849372 (2019).
- 81570Minh, B. Q., Nguyen, M. A. & von Haeseler, A. Ultrafast approximation for phylogenetic816bootstrap. Mol Biol Evol **30**, 1188-1195, doi:10.1093/molbev/mst024 (2013).
- 81771Knyazev, S. et al. Cliquesnv: Scalable reconstruction of intra-host viral populations from ngs818reads. bioRxiv. (2018).
- 819
 72
 Charles, O. J., Roberts, J., Breuer, J. & Goldstein, R. A. WeightedLD: The Application of

 820
 Sequence Weights to Linkage Disequilibrium. *bioRxiv*, 2021.2006.2004.447093,

 821
 doi:10.1101/2021.06.04.447093 (2021).
- 82273Martin, D. P. et al. RDP5: a computer program for analyzing recombination in, and removing823signals of recombination from, nucleotide sequence datasets. Virus Evol 7, veaa087,824doi:10.1093/ve/veaa087 (2021).

825 826

- 827 Table 1. Regimens and viral load at final timepoint for all patients. Patients initiated and maintained
- 1st-line regimens for between 1-10 years before being switched to 2nd-line regimens as part of the 828
- TasP trial. Eight of the nine patients were failing 2nd-line regimens at the final timepoint. 829

Patient	No. of timepoints	1st-line regimen	Time since initiation of 1 st - line treatment (yrs.)	2 nd -line regimen	Viral Load at final timepoint (copies/ml)
15664	6	d4T, 3TC, FTC	6.2	LPV/r, TDF, FTC	28655
16207	5	d4T, 3TC, NVP	5.9	LPV/r, TDF, FTC	56660
22763	8	d4T, 3TC, EFV	6.2	LPV/r, TDF, 3TC	15017
22828	6	d4T, 3TC, NVP	6.4	LPV/r, TDF, 3TC/FTC	947
26892	7	d4T, 3TC, EFV	6	LPV/r, TDF, FTC	12221
28545	5	TDF, FTC, EFV	1.3	LPV/r, AZT, 3TC	12964
29447	4	TDF, FTC, EFV	2.8	LPV/r, TDF, FTC	64362
47939	3	d4T, 3TC, EFV	10.1	LPV/r, AZT, 3TC/FTC	6328

831 NRTI: Stavudine, d4T; Lamivudine, 3TC; Tenofovir, TDF; Emtricitabine, FTC; Zidovudine, AZT. NNRTI: 832

- Efavirenz, EFV; Nevirapine, NVP. PI: Lopinavir/ritonavir, LPV/r.
- 833
- 834

835 Legends

836 Figure 1. Sequence divergence for eight Patients under non-suppressive ART. These data were for 837 SNPs detected by Illumina NGS at <2% abundance. Sites had coverage of at least 10 reads. In both a) 838 synonymous and **b**) non-synonymous mutations, there was idiosyncratic change in number of SNPs 839 relative to the reference strain over time. C) Mixed effects linear model of divergence from the 840 baseline timepoint and D) consensus C subtype.

841

842 Figure 2. Multi-dimensional scaling showing A) clustering of HIV whole genomes from consensus 843 sequences with high intra-Patient diversity. Multi-dimensional scaling (MDS) were created by 844 determining all pairwise distance comparisons under a TN93 substitution model, coloured by 845 Patient. Axis are MDS-1 and MDS-2. B) Maximum likelihood phylogeny of constructed viral 846 haplotypes for all Patients. The phylogeny was rooted on the AF411967 clade C reference genome. 847 Reconstructed haplotypes were genetically diverse and did not typically cluster by timepoint.

848

849 Figure 3A) Pairwise linkage disequilibrium decays rapidly with increasing distance between SNPs. 850 Lines represent patterns of LD for each patient examined in-depth. There was a constant decrease in 851 linkage disequilibrium over the first 800bp. B) Putative recombination breakpoints and drug-852 resistance associated mutations of all longitudinal consensus sequences belonging to three 853 Patients: 15664, 16207 and 22763. All sequences were coloured uniquely; perceived recombination 854 events supported by 4 or more methods implemented in RDP5 are highlighted with a red border and

italic text to show the major parent and recombinant portion of the sequence. Drug-resistance
associated mutations are indicated with a red arrow, relative to the key at the bottom of the image.
For ease of distinguishment, the K65R mutations is indicated with a blue arrow.

858

859 Figure 4. Drug regimen, adherence and viral dynamics within Patient 15664. a) Viral load and drug 860 levels. At successive timepoints drug regimen was noted and plasma drug concentration measured by HPLC (nmol/l). The Patient was characterised by multiple partial suppression (<750 copies/ml, 16 861 862 months; <250 copies/ml, 22 months) and rebound events (red dotted line) and poor adherence to 863 the drug regimen. b) Drug resistance and non-drug resistance associated non-synonymous 864 mutation frequencies by Illumina NGS. The Patient had large population shifts between timepoints 865 1-2, consistent with a hard selective sweep, coincident with the shift from 1^{st} -line regimen to 2^{nd} -866 line. c) Synonymous mutation frequencies. All mutations with a frequency of <10% or >90% at two 867 or more timepoints were tracked over successive timepoints. Most changes were restricted to gag 868 and pol regions and had limited shifts in frequency i.e. between 20-60%. d) Maximum-likelihood 869 phylogeny of reconstructed haplotypes. Haplotypes largely segregated into three major clades 870 (labelled A-C). Majority and minority haplotypes, some carrying lamivudine resistance mutation 871 M184V. Clades referred to in the text body are shown to the right of the heatmap.

872

873 Figure 5. Drug regimen, adherence and viral dynamics within Patient 16207. A) Viral load and drug 874 levels. At successive timepoints regimen was noted and plasma drug concentration measured by 875 HPLC (nmol/l). The Patient displayed ongoing viraemia and poor adherence to the prescribed drug 876 regimen. B) Drug resistance and non-drug resistance associated non-synonymous mutations 877 frequencies. The Patient had only one major RT mutation - K103N for the duration of the treatment 878 period. Several antagonistic non-synonymous switches in predominantly env were observed 879 between timepoints 1-4. C) Synonymous mutation frequencies. All mutations with a frequency of 880 <10% or >90% at two or more timepoints were followed over successive timepoints. In contrast to 881 non-synonymous mutations, most synonymous changes were in *pol*, indicative of linkage to the env 882 coding changes. D) Maximum-likelihood phylogeny of reconstructed haplotypes. Haplotypes were 883 again clearly divided intro three distinct clades; each clade contained haplotypes from all timepoints, 884 suggesting lack of hard selective sweeps and intermingling of viral haplotypes with softer sweeps. 885 that most viral competition occurred outside of drug pressure.

886

887 Figure 6. Drug regimen, adherence and viral dynamics of Patient 22763. A) Viral load and regimen 888 adherence. At successive timepoints the regimen was noted, and plasma drug concentration 889 measured by HPLC (nmol/l). The Patient had therapeutic levels of drug at several timepoints (3, 5 890 and 8), indicating variable adherence to the prescribed drug regimen. B) Drug resistance and non-891 drug-resistance-associated non-synonymous mutation frequencies. The Patient had numerous 892 drug resistance mutations in dynamic flux. Between timepoints 4-7, there was a complete 893 population shift, indicated by reciprocal competition between the RT mutations K65R and the TAMs 894 K67N and K70R. C) Synonymous mutations frequencies. All mutations with a frequency of <10% or 895 >90% at two or more timepoints were followed over successive timepoints. Several env mutations 896 mimicked the non-synonymous shifts observed between timepoints 2-4, suggestive of linkage. D) 897 Maximum-likelihood phylogeny of reconstructed haplotypes. timepoints 1-4 were found in distinct 898 lineages. In later timepoints, from 5-8, haplotypes became more intermingled, whilst maintaining 899 antagonism between K65R and K67N bearing viruses.

900

Supplementary Figure 1. Read depth per site for all BAM files. Any site that had coverage of <100
 reads (indicated as a horizontal black line) was excluded from haplotype reconstruction and
 reversion to consensus calculations.

904

905 **Supplementary Figure 2**. Whole-genome nucleotide diversity of longitudinal timepoints from each 906 patient. Diversity was calculated using all information from BAM files by fitting observed variant 907 frequencies to two distributions (a β -distribution and 4D Dirichlet plus Δ function). Each dot in the 908 scatter represents a different timepoint and highlights differences in whole-genome diversity 909 between successive timepoints.

910

916

911 Supplementary Figure 3. Maximum likelihood phylogeny of consensus sequences from all 912 timepoints from all patients. Phylogenies were rooted on a South-African origin subtype C reference 913 genome, AF411967. Trees were inferred with a GTR model with 1000 rapid bootstrap replicates. 914 Bootstrap values are indicated at all nodes. The phylogeny is consistent with the haplotype tree 915 shown in Figure 1C indicating that haplotypes were accurate representations of sequences.

917 **Supplementary Figure 4. MDS scatterplot of reconstructed haplotypes.** Plots were produced by 918 obtaining a multiple sequence alignment, calculating average pairwise distances between all pairs 919 and then multi-dimensional scaling under a TN93 substitution matrix. Each axis represents the 920 component scores of the most variable axis and the second-most variable axis. Haplotypes show an 921 increased measure of diversity compared to consensus-level variants. This is due to increased 922 resolution of potential viral quasispecies.

923

924 Supplementary Figure 5. Patterns of SNPs at perceived recombination breakpoint locations. In all 925 Patients where there was recombination detected, there were distinct patterns or haplotypes 926 observable across multiple sites. Distinct patterns were observable between recombination 927 breakpoints, lending support to the theory that recombination between different genomes was 928 occurring, to give rise to numerous haplotypes. In numerical terms where each number represents 929 an individual pattern (i.e. 0, 1 or 2), Patient 15664 haplotype pattern 1, (A, Left), assumes a 011011 930 distribution, pattern 2 (A, middle) as 0100010 and pattern 3 (A, right) as 000001. Patient 16207, 931 pattern one (B, Left) is 010223 and pattern 2 (B, right) is 010101. Patient 22763, pattern one (C, left) 932 is 00011211 and pattern 2 (C, right) is 00011210.

933

Supplementary Figure 6. Maximum-likelihood phylogenies of reconstructed haplotypes using
 Clique-SNV. As this method of haplotype reconstruction does not consider the longitudinal aspect of
 the data, haplotypes are segregated according to timepoint. DRMs are largely consistent with those
 inferred by HaROLD.

938

943

945

947

949

951

953

955

Supplementary Table 1a. Patient 15664 gag variant frequencies across successive timepoints. For all
 tables below, figures are in percentage of variant in a VCF at each timepoint.

- 942 **Supplementary Table 1b.** Patient 15664 *pol* variants.
- 944 **Supplementary Table 1C.** Patient 15664 *env* variants.
- 946 **Supplementary Table 2a**. Patient 16207 gag variant frequencies
- 948 **Supplementary Table 2b.** Patient 16207 *pol* variant frequencies.
- 950 Supplementary Table 2c. Patient 16207 *env* variant frequencies.
- 952 Supplementary Table 3a. Patient 22763 gag variant frequencies
- 954 **Supplementary Table 3b.** Patient 22763 pol mutations
- 956 **Supplementary Table 3c**. Patient 22763 env mutations

- 957 Supplementary Table 2. Results from linear mixed effects models of effect of months on divergence
- 958 from founder virus.

959






Figure 1. Sequence divergence for eight participants under non-suppressive ART. These data were for SNPs detected by Illumina NGS at <2% abundance. Sites had coverage of at least 10 reads. In both **a**) synonymous and **b**) non-synonymous mutations, there was idiosyncratic change in number of SNPs relative to the reference strain over time. **C**) Mixed effects linear model of divergence from the baseline timepoint and **D**) consensus **C** subtype.




Figure 2. Multi-dimensional scaling showing A) clustering of HIV whole genomes from consensus sequences with high intra-participant diversity. Multi-dimensional scaling (MDS) were created by determining all pairwise distance comparisons under a TN93 substitution model, coloured by participant. Axis are MDS-1 and MDS-2. **B**) Maximum likelihood phylogeny of constructed viral haplotypes for all participants. The phylogeny was rooted on the AF411967 clade C reference genome. Reconstructed haplotypes were genetically diverse and did not typically cluster by timepoint.




Figure 3A) Pairwise linkage disequilibrium decays rapidly with increasing distance between SNPs. Lines represent patterns of LD for each patient examined in-depth. There was a constant decrease in linkage disequilibrium over the first 800bp. B) Putative recombination breakpoints and drug-resistance associated mutations of all longitudinal consensus sequences belonging to three participants: 15664, 16207 and 22763. All sequences were coloured uniquely uniquely; perceived recombination events supported by 4 or more methods implemented in RDP5 are highlighted with a red border and italic text to show the major parent and recombinant portion of the sequence. Drug-resistance associated mutations are indicated with a red arrow, relative to the key at the bottom of the image. For ease of distinguishment, the K65R mutations is indicated with a blue arrow.

K219Q M184V




Figure 4. Drug regimen, adherence and viral dynamics within participant 15664. a) Viral load and drug levels. At successive timepoints drug regimen was noted and plasma drug concentration measured by HPLC (nmol/l). The participant was characterised by multiple partial suppression (<750 copies/ml, 16 months; <250 copies/ml, 22 months) and rebound events (red dotted line) and poor adherence to the drug regimen. b) Drug resistance and non-drug resistance associated non-synonymous mutation frequencies by Illumina NGS. The participant had large population shifts between timepoints 1-2, consistent with a hard selective sweep, coincident with the shift from 1st-line regimen to 2nd-line. c) Synonymous mutation frequencies. All mutations with a frequency of <10% or >90% at two or more timepoints were tracked over successive timepoints. Most changes were restricted to *gag* and *pol* regions and had limited shifts in frequency i.e. between 20-60%. d) Maximum-likelihood phylogeny of reconstructed haplotypes. Haplotypes largely segregated into three major clades (labelled A-C). Majority and minority haplotypes, some carrying lamivudine resistance mutation M184V. Clades referred to in the text body are shown to the right of the heatmap.




Figure 5. Drug regimen, adherence and viral dynamics within participant 16207. A) Viral load and drug levels. At successive timepoints regimen was noted and plasma drug concentration measured by HPLC (nmol/l). The participant displayed ongoing viraemia and poor adherence to the prescribed drug regimen. B) Drug resistance and non-drug resistance associated non-synonymous mutations frequencies. The participant had only one major RT mutation - K103N for the duration of the treatment period. Several antagonistic non-synonymous switches in predominantly *env* were observed between timepoints 1-4. C) Synonymous mutation frequencies. All mutations with a frequency of <10% or >90% at two or more timepoints were followed over successive timepoints. In contrast to non-synonymous mutations, most synonymous changes were in *pol*, indicative of linkage to the env coding changes. D) Maximum-likelihood phylogeny of reconstructed haplotypes. Haplotypes were again clearly divided intro three distinct clades; each clade contained haplotypes from all timepoints, suggesting lack of hard selective sweeps and intermingling of viral haplotypes with softer sweeps. that most viral competition occurred outside of drug pressure.




Figure 6. Drug regimen, adherence and viral dynamics of participant 22763. A) Viral load and regimen adherence. At successive timepoints the regimen was noted, and plasma drug concentration measured by HPLC (nmol/l). The participant had therapeutic levels of drug at several timepoints (3, 5 and 8), indicating variable adherence to the prescribed drug regimen. **B) Drug resistance and non-drug-resistance-associated non-synonymous mutation frequencies.** The participant had numerous drug resistance mutations in dynamic flux. Between timepoints 4-7, there was a complete population shift, indicated by reciprocal competition between the RT mutations K65R and the TAMs K67N and K70R. **C) Synonymous mutations frequencies.** All mutations with a frequency of <10% or >90% at two or more timepoints were followed over successive timepoints. Several *env mutations* mimicked the non-synonymous shifts observed between timepoints 2-4, suggestive of linkage. **D) Maximum-likelihood phylogeny of reconstructed haplotypes.** timepoints 1-4 were found in distinct lineages. In later timepoints, from 5-8, haplotypes became more intermingled, whilst maintaining antagonism between K65R and K67N bearing viruses.